New vaccines for yellow fever and rabies enter first human tests
NCT ID NCT06998004
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tested two new vaccines—one for yellow fever and one for rabies—in 112 healthy adults aged 18 to 40. The main goal was to check safety and see how well the vaccines trigger an immune response. Participants received different doses or a placebo to help find the best balance of safety and effectiveness.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- AVX70120 (yellow fever vaccine) and AVX70481 (rabies vaccine)
- What this could lead to
- If successful, these vaccines could provide new options to prevent yellow fever and rabies, potentially improving protection for travelers and people in affected regions.
- What could go wrong
- This is a very early Phase 1 trial with only 112 healthy adults. The vaccines may not trigger a strong enough immune response or could have unexpected side effects. Much more testing is needed before they could be widely used.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 1
The first testing in people. Mainly checks safety and dose, usually in a small group.
- Participants
-
112 people
The number who actually took part.
- Started
-
Jun 2024
- Finished
-
Jan 2026
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 40 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Male or female between, and including, 18 and 40 years of age on the day of the Screening Visit * Healthy individual, as established by the Investigator * Able to read and understand the informed consent form, and written informed consent obtained from the participant * Participants who, in the opinion of the Investigator, can and will comply with the requirements of the protocol Exclusion Criteria: * Body Mass Index \<18.0 or \>32.0 kg/m2 * Use of any investigational or non-registered product other than the study intervention within 1 month preceding study vaccination, or planned use during the study period * Concurrently participating in another clinical study, at any time during the study period, in which the participant has been or will be exposed to an investigational or non-registered product * Administration / planned administration of any vaccine not foreseen by the study protocol within 1 month preceding study vaccination and up to Day 31 * Chronic administration of immunosuppressants or other immune-modifying drugs within 6 months preceding study vaccination, or planned chronic administration at any time during the study period * Planned administration of long-acting immune-modifying drugs at any time during the study period * Administration of immunoglobulins and / or any blood or blood-derived products within 3 months preceding study vaccination, or planned administration during the study period * Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history, family history or physical examination * History of or current autoimmune disease * Personal or family history of thymic pathology * History of any neurological disorders or seizures * History of any reaction or hypersensitivity likely to be exacerbated by any component of the investigational vaccines * Malignancies or lymphoproliferative disorders within previous 5 years * Moderate or severe acute disease in the opinion of the Investigator, and / or fever at the time of study intervention * Alcohol, prescription drug, or substance (ab)use that, in the opinion of the Investigator, might interfere with the study conduct or completion * Pregnant or lactating woman * Woman of childbearing potential who is not utilising a highly effective birth control method for at least 1 month preceding study vaccination, or planning to discontinue highly effective birth control methods during the study period. * Participants employed by the Sponsor, by the vendors working on behalf of the Sponsor, by the Investigator or the study site, or close relatives of research staff working on this study * Medical condition or use of medication(s) that can increase the risk of bleeding or haematoma * Any other condition or finding that the Investigator judges may interfere with study procedures or study results Note: other protocol-defined inclusion / exclusion criteria may apply.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Rabies are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Centre for the Evaluation of Vaccination (CEV)
Antwerp, Belgium
-
University Hospital Ghent - Centrum voor Vaccinologie (CEVAC)
Ghent, Belgium
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new yellow fever vaccine match the old one?
- Experimental antibody cocktail offers hope for rabies patients with no other options
- New antibody cocktail aims to stop rabies after multiple dog bites
- New yellow fever vaccine shows promise in Mid-Stage trial
- New yellow fever vaccine shows promise in early human trial
- New rabies vaccine shows promise in large trial